Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
24.89
+0.19 (0.77%)
Sep 23, 2026, 3:00 PM CST
SHA:605177 Revenue
Zhejiang East Asia Pharmaceutical had revenue of 201.57M CNY in the quarter ending June 30, 2026, a decrease of -10.39%. This brings the company's revenue in the last twelve months to 990.47M, up 2.55% year-over-year. In the year 2025, Zhejiang East Asia Pharmaceutical had annual revenue of 940.19M, down -21.54%.
Revenue (ttm)
990.47M
Revenue Growth
+2.55%
P/S Ratio
2.83
Revenue / Employee
654.21K
Employees
1,514
Market Cap
2.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 940.19M | -258.05M | -21.54% |
| Dec 31, 2024 | 1.20B | -158.21M | -11.66% |
| Dec 31, 2023 | 1.36B | 176.89M | 15.00% |
| Dec 31, 2022 | 1.18B | 467.34M | 65.62% |
| Dec 31, 2021 | 712.22M | -169.45M | -19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Guangdong VTR Bio-Tech | 814.07M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |